101083-92-5

Usage

Uses

Used in Pharmaceutical Industry:
5-NITRO-1H-PYRROLO[2,3-B]PYRIDINE is used as a reagent for the synthesis of Cdc7 kinase inhibitors, which are being explored as a novel cancer therapy. These inhibitors target the Cdc7 kinase enzyme, which plays a critical role in the regulation of DNA replication and cell cycle progression, making it a promising target for cancer treatment.
5-NITRO-1H-PYRROLO[2,3-B]PYRIDINE is also used as an intermediate in the synthesis of 4-anilinoquinazolines, a class of compounds with potential anticancer properties. These compounds have shown activity against various types of cancer, including solid tumors, by targeting specific cellular pathways and mechanisms involved in cancer cell growth and survival.

InChI:InChI=1/C7H5N3O2/c11-10(12)6-3-5-1-2-8-7(5)9-4-6/h1-4H,(H,8,9)

Upstream product

• 118600-53-6 5-nitro-7-azaindoline 
• 10592-27-5 7-azaindoline 
• 4214-76-0 5-nitro-pyridin-2-ylamine 
• 118600-52-5 1-nitro-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine 
• 937012-11-8 5-nitro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 271-63-6 7-Azaindole 
• 25391-56-4 3-iodo-5-nitropyridin-2-ylamine 
• 869884-26-4 2-amino-5-nitro-3-[(trimethylsilyl)ethynyl]pyridine 

Downstream Products

• 100960-07-4 1H-pyrrolo[2,3-b]pyridin-5-amine 
• 869371-00-6 5-amino-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one 
• 937012-15-2 5-nitro-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde 
• 1227935-14-9 phenyl 2-(5-nitro-1H-pyrrolo[2,3-b]pyridin-1-yl)acetate 
• 1146215-16-8 5-nitro-1-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridine 
• 1401447-95-7 9-(1-benzyl-3,6-dihydro-2H-pyridin-5-yl)-3H-pyrrolo[3,2-f][1,7]naphthyridine 
• 1146215-17-9 1-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridine-5-amine 
• 1401447-79-7 diethyl 2-[[[1-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-5-yl]amino]methylene]propanedioate 
• 1401447-71-9 ethyl 9-hydroxy-3-(p-tolylsulfonyl)pyrrolo[3,2-f][1,7]naphthyridine-8-carboxylate 
• 1401448-23-4 [1-[3-(p-tolylsulfonyl)pyrrolo[3,2-f][1,7]naphthyridin-9-yl]-4-piperidyl]methyl4-methylbenzenesulfonate 
• 1401448-24-5 S-[[1-[3-(p-tolylsulfonyl)pyrrolo[3,2-f][1,7]naphthyridin-9-yl]-4-piperidyl]methyl]ethanethioate 
• 1401448-25-6 [1-[3-(p-tolylsulfonyl)pyrrolo[3,2-f][1,7]naphthyridin-9-yl]-4-piperidyl]methanesulfonic acid 
• 1401448-26-7 9-[4-[[3-[(4-fluorophenoxy)methyl]-1-piperidyl]sulfonylmethyl]-1-piperidyl]-3-(p-tolylsulfonyl)pyrrolo[3,2-f][1,7]naphthyridine 
• 1401434-96-5 9-[4-[[3-[(4-fluorophenoxy)methyl]-1-piperidyl]sulfonylmethyl]-1-piperidyl]-3H-pyrrolo[3,2-f][1,7]naphthyridine 

Relevant academic research and scientific papers

Efficient and Scalable Process for Synthesis of 5-Nitro-7-azaindole

A simple and straightforward methodology for the synthesis of 5-nitro-7-azaindole 6 has been developed using metal-free cycloisomerization of 5-nitro-3-trimethylsilanylethynyl-pyridin-2-ylamine 18. Large-scale applicability of this newly developed method was successfully demonstrated on multikilogram scale to obtain 5-nitro-7-azaindole 6 in consistent yield and purity.

HEAT SHOCK PROTEIN 90 INHIBITORS

Substituted aromatic compounds of formula (I) shown below: (formula I) The definition of each variable in formula (I) appears in the Specification. Also disclosed is a pharmaceutical composition containing one of the substituted aromatic compounds. Further disclosed is a method of using one of these compounds for treating a medical condition associated with HSP90.

SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

The present invention relates to substituted fused tricyclic compounds of formula (I) or (Ia), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by JAK activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by JAK activity. Such conditions include, but not limited to, arthritis, Alzheimer's disease, autoimmune thyroid disorders, cancer, diabetes, leukemia, T-cell prolymphocytic leukemia, lymphoma, myleoproliferation disorders, lupus, multiple myeloma, multiple sclerosis, osteoarthritis, sepsis, psoriatic arthritis, prostate cancer, T-cell autoimmune disease, inflammatory diseases, chronic and acute allograft transplant rejection, bone marrow transplant, stroke, asthma, chronic obstructive pulmonary disease, allergy, bronchitis, viral diseases, or Type I diabetes, complications from diabetes, rheumatoid arthritis, asthma, Crohn's disease, dry eye, uveitis, inflammatory bowel disease, organ transplant rejection, psoriasis and ulcerative colitis. The present disclosure also relates to process for the preparation of such compounds, and to pharmaceutical compositions containing them.

HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS

Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

The present invention is directed to compounds of the formula or pharmaceutically acceptable salts, prodrug, solvate or optical isomer thereof, pharmaceutical compositions containing same and use thereof for treating diseases linked to disregulated cell p

A practical, efficient synthesis of 5-amino-7-azaindole

A much improved, workable synthesis of 5-amino-7-azaindole is described in 66% overall yield starting from 2-amino-5-nitropyridine. The key stage involves a microwave promoted heteroannulation reaction of a pyridine alkyne. Georg Thieme Verlag Stuttgart.